baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Bristol Myers Squibb Co/ US1101221083 /

2024-10-17 10:10:00 PM	Chg. -0.19	Volume	Bid10:44:31 AM	Ask10:44:31 AM	Market Capitalization	Dividend Y.	P/E Ratio
53.18USD	-0.36%	7.95 mill. Turnover: 329.02 mill.	53.05Bid Size: 1,300	53.22Ask Size: 100	107.82 bill.USD	4.34%	13.71

GlobeNewswire 09-03 Amphista Therapeutics appoints Antony Mattessich as Chief Executive Officer

GlobeNewswire 09-02 CSE Announces its 2024 Sustainability & ESG Leadership Summit at NYC's One World Trade Center

GlobeNewswire 08-30 Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire 08-29 Immunocore announces transition of Chief Financial Officer

GlobeNewswire 08-28 Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...

GlobeNewswire 08-22 Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...

GlobeNewswire 08-15 Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...

GlobeNewswire 08-12 Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...

Newsfile Corp 08-12 The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors

GlobeNewswire 08-12 Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer

GlobeNewswire 08-08 CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 08-07 Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Diseas...

GlobeNewswire 08-06 ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors

GlobeNewswire 08-05 iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

GlobeNewswire 08-01 Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...

GlobeNewswire 08-01 CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024

GlobeNewswire 07-31 Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Boar...

GlobeNewswire 07-30 Anaveon appoints Dieter Weinand as Chair of its Board of Directors

GlobeNewswire 07-25 Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule

GlobeNewswire 07-24 Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado

GlobeNewswire 07-20 NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program

GlobeNewswire 07-17 Nouscom Appoints Tiffany Muller as Chief Financial Officer and Loredana Siani as Senior Vice Preside...

GlobeNewswire 07-09 VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clin...

GlobeNewswire 07-09 Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

GlobeNewswire 07-08 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Bristol Myers Squibb Co/ US1101221083 /

If you wish to receive reply to your feedback, please provide your email address.